5323002025-10-012025-12-315323002025-12-315323002025-04-012025-12-315323002025-10-012025-12-31in-capmkt:OtherExpenses1Member5323002025-10-012025-12-31in-capmkt:OtherExpenses2Member5323002025-04-012025-12-31in-capmkt:OtherExpenses1Member5323002025-04-012025-12-31in-capmkt:OtherExpenses2Member5323002025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15323002025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15323002025-12-31Statement15323002025-10-012025-12-31Statement15323002025-12-31StatementDynamic1I1Statement15323002025-12-31StatementDynamic1I2Statement15323002025-12-31StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532300WOCKPHARMANAINE049B01025Wockhardt LimitedMain BoardEquity2025-04-012026-03-312026-02-102026-02-04INRCroresQuarterlyThird quarterSingle segmentPharmaceuticals2026-02-1011:45:002026-02-1014:15:00Not applicabletrue1falseNot Applicable as there is no default on loans and the company has no outstanding debt securities as on 31.12.2025.2025-10-012025-12-31UnauditedStandalone43000000002700000004570000000810000000670000000-38000000078000000050000000052000000012900000004190000000380000000-10000000028000000000002800000000000280000000-1000000027000000081000000051.731.73001.731.730001)The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 10, 2026. The results have been subjected to limited review by the Statutory Auditors of the Company. <BR> 2)Effective November 21,2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes ('Code'). All set of rules under the Code are yet to be notified.The Company has assessed and accounted the incremental impact of the new Code based on the best available information and actuarial valuation amounting to Rs. 10 crores as 'Exceptional items' for the quarter ended December 31, 2025. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect as and when such clarifications are issued / rules are notified. <BR> 3)The Company is exclusively into Pharmaceutical business segment2025-04-012025-12-31UnauditedStandalone122300000008200000001305000000023000000001580000000-9300000002340000000135000000014300000003380000000114500000001600000000-10000000015000000000000150000000000001500000000-10000000149000000081000000059.249.24009.249.24000Exchange fluctuation loss, net0Other expenses1290000000Exchange fluctuation loss, net0Other expenses3380000000Items that will not be reclassified to Profit or Loss - charge (consisting of re-measurement of net defined benefit liability)-10000000-10000000Items that will not be reclassified to Profit or Loss - charge (consisting of re-measurement of net defined benefit liability)-10000000-100000000000-10000000-10000000QIP2024-11-11100000000002025-12-31trueCRISIL RATINGS LIMITEDfalseNANILNILRashmi MamturaCompany Secretary and Compliance OfficerMumbai2026-02-10Repayment and / or pre – payment, in full or part, of certain borrowings availed by the CompanyNO5000000000049459000000Funding of capital expenditure, investment in research and development and incidental expensesNO250000000007287000000General Corporate PurposesNO2239700000227790000019983000000